Hair loss clinical trials recruiting now
144 recruiting studies in alopecia, from ClinicalTrials.gov: phase, sponsor, country, and the programme in the register each one belongs to. Refreshed nightly.
- NCT07711574Unknown
Prevalence of Depression Among Patients With Alopecia Areata
Sohag University · Target enrolment: 100 · Sep 2027 · Egypt
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Eurofarma Laboratorios S.A. · Target enrolment: 372 · Jan 2027
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
Eurofarma Laboratorios S.A. · Target enrolment: 372 · Jan 2027
- NCT07758400Unknown
A Study on the Efficacy and Safety of Microneedling for Male Androgenetic Alopecia
Cheng Zhou · Target enrolment: 190 · Jan 2027 · China
- NCT07739147Phase 0
Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial
Kimberly Meathrel · Target enrolment: 30 · Dec 2026
XVIE to Treat Androgenetic Alopecia (AGA)
Restore Biologics Holdings, Inc. dba Xtressé · Target enrolment: 30 · Dec 2026 · United States
- NCT07594678Phase 2
Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients
Ohio State University Comprehensive Cancer Center · Target enrolment: 50 · Nov 2026 · United States
- NCT07839494Unknown
A Clinical Trial to Investigate the Efficacy of BioCopper1®, Restore Cu1, and Grow + Restore Cu1 on Hair and Skin Improvements in Healthy Adults
Mitosynergy LLC · Target enrolment: 88 · Nov 2026 · Canada
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
Apsen Farmaceutica S.A. · Target enrolment: 336 · Oct 2026 · Brazil
- NCT03474718Phase 0
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
Wake Forest University Health Sciences · Target enrolment: 16 · Oct 2026 · United States
- NCT07453238Approved
Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata
Hayat Abad Medical Complex, Peshawar · Target enrolment: 60 · Oct 2026
- NCT07705217Unknown
The Role of Gut and Skin Microbiota in Alopecia Areata
Polyclinic GrandMed · Target enrolment: 30 · Oct 2026 · Croatia
- NCT07817277Unknown
Hair Changes in Females With Type 2 Diabetes Clinical and Trichoscopic Examination
Al-Azhar University · Target enrolment: 130 · Oct 2026 · Egypt
- NCT07835646Unknown
Evaluation of the Dietary Supplement Effect on Improvement of Hair Condition in Subjects With Occasional Hair Loss.
Lacer S.A. · Target enrolment: 60 · Oct 2026 · Spain
- NCT07850011Unknown
Evidence-Based Integrated Protocol to Maximize Hair Follicle Survival in Follicular Unit Extraction (FUE)
Assiut University · Target enrolment: 30 · Oct 2026
- NCT07783113Unknown
Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use
Farmoquimica S.A. · Target enrolment: 48 · Oct 2026 · Brazil
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
Jiangsu vcare pharmaceutical technology co., LTD · Target enrolment: 24 · Sep 2026 · China
- NCT07806474Unknown
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
Activ'inside · Target enrolment: 99 · Sep 2026 · Italy
- NCT07637071Unknown
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
Restore Biologics Holdings, Inc. dba Xtressé · Target enrolment: 48 · Sep 2026 · United States
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Pelage Pharmaceuticals, Inc. · Target enrolment: 600 · Sep 2026 · United States, Canada
- NCT07734870Phase 2
Tirzepatide for Treatment of CCCA
Johns Hopkins University · Target enrolment: 20 · Sep 2026 · United States
Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)
Maryanne Makredes Senna · Target enrolment: 30 · Sep 2026 · United States
- NCT07474558Phase 2
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
Jules Bordet Institute · Target enrolment: 102 · Sep 2026 · Belgium
- NCT07809191Unknown
Hair Regrowth Following Partial Thickness Removal of SSCIS
The Cooper Health System · Target enrolment: 15 · Sep 2026
- NCT07748169Unknown
An Observational Study of Patients With Dermatologic Disease
Target PharmaSolutions, Inc. · Target enrolment: 2000000 · Sep 2026 · United States
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
AbbVie · Target enrolment: 300 · Aug 2026 · United States, Taiwan
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
Jiangsu vcare pharmaceutical technology co., LTD · Target enrolment: 120 · Aug 2026 · China
- NCT07716748Unknown
For an Investigator-led Hair Study Comparing Between Healthy and Hair Loss Volunteers
National Skin Centre · Target enrolment: 66 · Aug 2026
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
Pfizer · Target enrolment: 336 · Jul 2026 · United States, Canada, Japan
- NCT07803874Unknown
UV-Trichoscopic Red Fluorescence in Alopecia Areata
Istanbul Training and Research Hospital · Target enrolment: 40 · Jul 2026 · Turkey
- NCT07696585Unknown
New Topical Treatment in Patchy Alopecia Areata
Sohag University · Target enrolment: 60 · Jun 2026
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Sun Pharma Japan Limited · Target enrolment: 78 · Jun 2026 · Japan
- NCT07733063Unknown
Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata
Istanbul Training and Research Hospital · Target enrolment: 156 · Jun 2026 · Turkey
Deucravacitinib in the Treatment of Cicatricial Alopecias
Icahn School of Medicine at Mount Sinai · Target enrolment: 20 · May 2026 · United States
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
Icahn School of Medicine at Mount Sinai · Target enrolment: 30 · May 2026 · United States
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Applied Biology, Inc. · Target enrolment: 60 · May 2026 · Brazil, Italy
- NCT07536100Unknown
VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia
Institute of Dermatology, Thailand · Target enrolment: 80 · May 2026 · Thailand
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
Applied Biology, Inc. · Target enrolment: 1120 · May 2026
- NCT07693244Phase 2
Exosome Therapy for Male Androgenetic Alopecia
Zhang Han · Target enrolment: 120 · Apr 2026 · China
- NCT07340671Unknown
Facial Papules in Frontal Fibrosing Alopecia (FFA)
University of Miami · Target enrolment: 10 · Apr 2026 · United States
- NCT07294313Unknown
Harnessing Artificial Intelligence for Diagnosing Androgenetic Alopecia: A Training and Validation Study
Cairo University · Target enrolment: 400 · Apr 2026 · Egypt
- NCT07554222Phase 1
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
Innovent Biologics (Suzhou) Co. Ltd. · Target enrolment: 160 · Apr 2026 · China
Pharmacokinetic Study of DA-020
Applied Biology, Inc. · Target enrolment: 60 · Apr 2026 · Brazil, Italy
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Eli Lilly and Company · Target enrolment: 60 · Apr 2026 · United States, Canada, China, Netherlands
- NCT07499713Unknown
Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata
Istanbul Training and Research Hospital · Target enrolment: 90 · Apr 2026 · Turkey
- NCT07268534Phase 2
Biologics in Folliculitis Decalvans : an Adaptative Trial Research
Assistance Publique - Hôpitaux de Paris · Target enrolment: 120 · Apr 2026
Androgenic Alopecia TH07 Clinical Trial
Triple Hair Inc · Target enrolment: 420 · Apr 2026 · Canada
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
Moogene Medi Co., Ltd · Target enrolment: 30 · Apr 2026 · South Korea
- NCT07518342Approved
The Effect of Nanofat Injection on Androgenetic Alopecia
Assiut University · Target enrolment: 60 · Apr 2026 · Egypt
- NCT07810504Unknown
Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy
K. Kay Durairaj, MD, FACS, A Medical Corporation · Target enrolment: 40 · Mar 2026 · United States
- NCT07484061Unknown
Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists
Olistic Research Labs S.L. · Target enrolment: 40 · Mar 2026 · Spain
- NCT07459933Approved
Topical Methotrexate vs Minoxidil for Localized Alopecia Areata
Jinnah Postgraduate Medical Centre · Target enrolment: 268 · Mar 2026
- NCT07603544Unknown
Multi-Omics Insights Into Androgenetic Alopecia
The First Affiliated Hospital of Xinxiang Medical College · Target enrolment: 12 · Mar 2026 · China
- NCT07422376Unknown
Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region
Charles Mays · Target enrolment: 100 · Mar 2026 · United States
- NCT07406204Approved
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
Hayat Abad Medical Complex, Peshawar · Target enrolment: 78 · Feb 2026
- NCT07368842Unknown
Scalp Hair Metabolomics in Severe Obesity
Singapore General Hospital · Target enrolment: 60 · Feb 2026 · Singapore
- NCT07563036Unknown
JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
Kasr El Aini Hospital · Target enrolment: 25 · Feb 2026 · Egypt
- NCT07370519Phase 2
Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia
Shenzhen People's Hospital · Target enrolment: 388 · Jan 2026 · China
Study of EPI-001 in Patients With Androgenetic Alopecia
Epibiotech · Target enrolment: 42 · Jan 2026 · South Korea
- NCT07242638Phase 2
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Icahn School of Medicine at Mount Sinai · Target enrolment: 56 · Jan 2026 · United States
- NCT07429253Phase 1/2
Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients
PT. Prodia Stem Cell Indonesia · Target enrolment: 40 · Jan 2026 · Indonesia
- NCT07287579Unknown
Comparison Between Platelet Rich Plasma and Nanofat as an Adjuvant Therapy in HairTransplantation
Sohag University · Target enrolment: 30 · Jan 2026
- NCT07502976Unknown
Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia
Kasr El Aini Hospital · Target enrolment: 60 · Jan 2026 · Egypt
- NCT07336641Unknown
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
Fondazione ISIDE · Target enrolment: 20000 · Jan 2026 · Italy
Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia
Sheikh Zayed Federal Postgraduate Medical Institute · Target enrolment: 200 · Dec 2025
A Study of LAD603 in Adults With Alopecia Areata
Almirall, S.A. · Target enrolment: 136 · Dec 2025 · United States
- NCT07250997Unknown
PALLAS Laser for Skin Diseases
Szeged University · Target enrolment: 50 · Dec 2025 · Hungary
- NCT06946550Unknown
Non-Ablative Laser to Treat Scarring Alopecia With Hair Follicle Gene Expression Analysis
Montefiore Medical Center · Target enrolment: 5 · Dec 2025 · United States
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
Olix Pharmaceuticals, Inc. · Target enrolment: 158 · Dec 2025 · Australia
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
Absci Pty Ltd. · Target enrolment: 227 · Dec 2025 · Australia
- NCT07248410Unknown
A Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia
Chang Gung Memorial Hospital · Target enrolment: 30 · Nov 2025 · Taiwan
- NCT07144345Phase 3
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Sun Pharmaceutical Industries, Inc. · Target enrolment: 160 · Nov 2025 · United States
- NCT07190534Unknown
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
Erasmus Medical Center · Target enrolment: 50 · Nov 2025 · Netherlands
- NCT07381556Approved
Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
Erasmus Medical Center · Target enrolment: 50 · Nov 2025 · Netherlands
- NCT07205159Phase 1
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Forte Biosciences, Inc. · Target enrolment: 32 · Oct 2025 · Australia, New Zealand
- NCT07107841Unknown
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
Acorn Biolabs Inc. · Target enrolment: 60 · Oct 2025 · United States
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
Applied Biology, Inc. · Target enrolment: 140 · Oct 2025 · Italy
- NCT06998433Approved
Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia
Baylor College of Medicine · Target enrolment: 56 · Sep 2025 · United States
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
Restore Biologics Holdings, Inc. dba Xtressé · Target enrolment: 15 · Sep 2025 · United States
- NCT07203599Phase 1/2
A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes
Shenzhen People's Hospital · Target enrolment: 59 · Sep 2025 · China
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer · Target enrolment: 140 · Sep 2025 · United States, China, Czechia, France
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
AbbVie · Target enrolment: 2795 · Sep 2025 · Argentina, Canada, Colombia, Czechia
- NCT07112586Phase 1/2
Evaluation of Exosomes Injection in Treatment of Male Androgenetic Alopecia: Clinical and Immunohistochemical Study
Ain Shams University · Target enrolment: 15 · Aug 2025 · Egypt
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
Pfizer · Target enrolment: 3000 · Aug 2025 · South Korea
- NCT06747611Phase 2
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
University of Minnesota · Target enrolment: 40 · Aug 2025 · United States
- NCT07049328Phase 1
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
HCW Biologics · Target enrolment: 30 · Aug 2025 · United States
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc. · Target enrolment: 355 · Aug 2025 · United States, Canada
- NCT06869252Phase 1/2
Autologous Adipose Cells Therapy
CERM INC. · Target enrolment: 40 · Aug 2025 · United States
- NCT06998680Unknown
6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair
Vita Green Pharmaceutical (H.K.) Ltd. · Target enrolment: 152 · Jul 2025 · China
Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia
Cairo University · Target enrolment: 25 · Jul 2025 · Egypt
Pharmacokinetic Study of Topical Phenylephrine
Applied Biology, Inc. · Target enrolment: 24 · Jun 2025 · Italy
Low Dose Oral Minoxdil in Androgenic Alopecia
Jinnah Postgraduate Medical Centre · Target enrolment: 76 · Jun 2025 · Pakistan
Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
Shanghai Zhongshan Hospital · Target enrolment: 30 · Jun 2025 · China
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients
CSPC Ouyi Pharmaceutical Co., Ltd. · Target enrolment: 156 · May 2025
- NCT07041489Unknown
Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair
The Center for Clinical and Cosmetic Research · Target enrolment: 85 · May 2025 · United States
- NCT06926023Unknown
1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss
Goldman, Butterwick, Fitzpatrick and Groff · Target enrolment: 10 · May 2025 · United States
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
Chong Kun Dang Pharmaceutical · Target enrolment: 288 · Apr 2025 · South Korea
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer · Target enrolment: 674 · Apr 2025 · United States, Canada, China, Czechia
- NCT07224555Unknown
Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair
Restore Biologics Holdings, Inc. dba Xtressé · Target enrolment: 60 · Mar 2025 · United States
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
Aldena Therapeutics · Target enrolment: 24 · Mar 2025 · United States, Canada
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Target enrolment: 294 · Feb 2025 · China
- NCT06885112Unknown
Clinical Study to Evaluate the Improvement in Hair Loss in Skin of Color Treated With Fractional Non-Ablative Laser
Lumenis Be Ltd. · Target enrolment: 40 · Feb 2025 · United States
- NCT06818370Unknown
The Effect of Coconut Oil on Alopecia
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Target enrolment: 86 · Feb 2025 · Turkey
- NCT06801821Unknown
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Target enrolment: 400 · Feb 2025 · Italy
Various Procedural Treatment Options for Androgenetic Alopecia
Sheikh Zayed Medical College · Target enrolment: 190 · Feb 2025 · Pakistan
Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study
National Taiwan University Hospital · Target enrolment: 30 · Jan 2025 · Taiwan
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
Applied Biology, Inc. · Target enrolment: 516 · Jan 2025
Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
EMS · Target enrolment: 504 · Jan 2025 · Brazil
- NCT06764329Phase 1/2
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia.
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Target enrolment: 70 · Dec 2024 · Pakistan
- NCT06786078Unknown
The Lily Device Trial
Luminate Medical, Inc. · Target enrolment: 85 · Dec 2024 · United States
- NCT06292533Unknown
Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study
Universiti Tunku Abdul Rahman · Target enrolment: 92 · Dec 2024 · Malaysia
- NCT05484973Unknown
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
Cooler Heads Care Inc. · Target enrolment: 99 · Nov 2024 · United States
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
Suzhou Kintor Pharmaceutical Inc, · Target enrolment: 756 · Oct 2024 · China
- NCT06841458Unknown
Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers
Industrial Farmacéutica Cantabria, S.A. · Target enrolment: 45 · Oct 2024 · Spain
- NCT06399783Approved
Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata
Assiut University · Target enrolment: 54 · Oct 2024 · Egypt
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
NEXTGEN Bioscience · Target enrolment: 73 · Sep 2024 · South Korea
- NCT06573593Unknown
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Second Affiliated Hospital, Zhejiang University, School of Medicine · Target enrolment: 150 · Jul 2024 · China
- NCT05866562Phase 2
Dupilumab in the Treatment of Pediatric Alopecia Areata
Icahn School of Medicine at Mount Sinai · Target enrolment: 76 · Jul 2024 · United States
- NCT06562270Unknown
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
CorEvitas · Target enrolment: 1500 · Mar 2024 · United States
- NCT06326359Unknown
Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
Sohag University · Target enrolment: 40 · Mar 2024
- NCT06360718Unknown
Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
Children's Hospital Los Angeles · Target enrolment: 140 · Feb 2024 · United States
- NCT06283316Unknown
Systemic Treatments for Alopecia Areata Registry
Erasmus Medical Center · Target enrolment: 10000 · Jan 2024 · Netherlands
- NCT06327581Unknown
Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata
Zagazig University · Target enrolment: 88 · Dec 2023 · Egypt
- NCT05460611Unknown
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
Montefiore Medical Center · Target enrolment: 10 · Dec 2023 · United States
- NCT07079657Unknown
Thulium Laser and Growth Factors for Androgenetic Alopecia
Universitätsklinikum Hamburg-Eppendorf · Target enrolment: 30 · Dec 2023 · Germany
- NCT06955702Unknown
Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients
University of Salamanca · Target enrolment: 120 · Nov 2023 · Spain
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie · Target enrolment: 1500 · Oct 2023 · United States, Argentina, Australia, Belgium
- NCT06046651Unknown
Blood Specimen Collection For Laboratory Assay Research
Roman Health Ventures Inc. · Target enrolment: 10000 · Aug 2023 · United States
- NCT05928169Unknown
Determinants of Chronic Inflammatory Skin Disease Trajectories
University Hospital Schleswig-Holstein · Target enrolment: 1000 · May 2023 · Germany
- NCT05551793Phase 2
Regeneron AA Multicenter (Dupilumab)
Emma Guttman · Target enrolment: 76 · Apr 2023 · United States
- NCT05417308Phase 0
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
Ohio State University Comprehensive Cancer Center · Target enrolment: 50 · Mar 2023 · United States
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company · Target enrolment: 595 · Feb 2023 · United States, Argentina, Australia, Canada
Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia
EMS · Target enrolment: 190 · Feb 2023 · Brazil
- NCT05398809Phase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
National Institute of Allergy and Infectious Diseases (NIAID) · Target enrolment: 70 · Jan 2023 · United States
- NCT05745389Unknown
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
CorEvitas · Target enrolment: 5000 · Oct 2022 · United States
- NCT05213936Unknown
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
Montefiore Medical Center · Target enrolment: 41 · Oct 2022 · United States
- NCT05177289Unknown
Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia
Jessa Hospital · Target enrolment: 72 · Feb 2022 · Belgium
- NCT04986579Phase 2
Scalp Cooling in MBC
Dana-Farber Cancer Institute · Target enrolment: 120 · Oct 2021 · United States
- NCT04764331Unknown
A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
Wake Forest University Health Sciences · Target enrolment: 5 · Jul 2021 · United States
- NCT04764357Unknown
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
St. Jude Children's Research Hospital · Target enrolment: 40 · Jun 2021 · United States
Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
University Hospital, Bordeaux · Target enrolment: 450 · Jan 2020 · France
- NCT04014413Unknown
Safety and Efficacy of Fecal Microbiota Transplantation
Chinese University of Hong Kong · Target enrolment: 450 · Jul 2019 · Hong Kong
- NCT04207931Approved
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study
Wake Forest University Health Sciences · Target enrolment: 250 · Apr 2018 · United States
- NCT05938569Unknown
Computer-Assisted Hair Restoration Study Using ARTAS System
Venus Concept · Target enrolment: 150 · Nov 2016 · United States
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.